The critique discusses 58 peptides in several clinical phases, indicating a robust pipeline of peptide therapies concentrating on PPIs. These approaches open new avenues for treatments personalized to battle distinct breast most cancers subtypes and glioblastoma by honing in on integrins, fibronectins, and matrix metalloproteinases. Article m